NAPLEX (North American Pharmacist Licensure Examination) Practice Exam

Disable ads (and more) with a membership for a one time $2.99 payment

Study for the NAPLEX exam with a comprehensive quiz featuring multiple-choice questions and in-depth explanations. Build your pharmacological knowledge and increase your chances of passing the pharmacist licensure examination!

Each practice test/flash card set has 50 randomly selected questions from a bank of over 500. You'll get a new set of questions each time!

Practice this question and more.

What does Carfilzomib inhibit?

DNA replication
Angiogenesis
Proteosomes
EGFR

The correct answer is: Proteosomes

Carfilzomib inhibits proteosomes, specifically the chymotrypsin-like activity of the 20S proteasome. This is important in cancer treatment, as it targets the breakdown of proteins, which can contribute to cancer cell growth. Neither DNA replication, angiogenesis, nor EGFR are inhibited by carfilzomib. DNA replication is a central process in cell division and is targeted by some chemotherapy drugs, but not carfilzomib. Angiogenesis is the formation of new blood vessels, which plays a role in cancer growth, but this is not directly inhibited by carfilzomib. EGFR (epidermal growth factor receptor) is a protein involved in cell signaling and is often mutated in cancer, but carfilzomib does not specifically target EGFR.